Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 1038Cyclophosphamide 972Carboplatin 952Radiotherapy 890Bevacizumab 845Gemcitabine 817pembrolizumab 758Paclitaxel 738Docetaxel 733Oxaliplatin 704Capecitabine 646Fluorouracil 563Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 400Leucovorin 376Cytarabine 342Cetuximab 338Lenalidomide 326Trastuzumab 321Pemetrexed 314durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 277Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Sampling Studies × Clear all
NCT04666090 2025-05-15

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡